Cannabinoid actives

Elevate patient health and convenience

Want to navigate pharma cannabidiol (CBD) and cannabinoid-based research and development with confidence? As an end-to-end partner, we can help enhance the odds of therapeutic breakthroughs and streamline development pathways in the cannabinoids space.

Along with our strategic partner and leading manufacturer of high-quality cannabinoids, Brains Bioceutical, we offer a unique innovation platform. It’s powered by CBtru®, a pioneering cannabidiol (CBD) drug product intermediate, and our full suite of technical, quality, regulatory, and other expert services. Together, we can realize the potential of cannabinoid-based therapies to unlock new treatment possibilities and innovative dosage forms for patients worldwide.

Discover CBtru®

CBtru® is a premium formulated CBD drug product intermediate and patent-pending solution that presents patients, healthcare professionals, and pharmaceutical product manufacturers with exciting opportunities. Learn how CBtru® addresses common formulation challenges from bioavailability to convenience and compliance.

Learn more

We deliver more than cannabinoid ingredients

In fact, we can support you throughout the entire research and drug development journey. Find out how we can help you avoid potential pitfalls and elevate your next cannabinoid-based innovation.

Download brochure

In the fertility laboratory the Doctor preparing embryo cultivation plates

Due diligence considerations in drug development

Cannabinoid-based innovation may be complex, but it doesn’t need to be. Discover strategies to succeed at each step of drug discovery and development—from choosing the right API to fine-tuning patient experience.

Download whitepaper

Webinars

Best practices in CBD research and development

CBD and other cannabinoids hold great therapeutic promise. But currently available drug delivery formats face challenges, like API absorption. Learn how to optimize CBD bioavailability.

Watch webinar

The future of cannabinoid research and development

What’s next in cannabinoid-based R&D and product innovation? Find out in this on-demand Future Scientific Horizons panel discussion from ICBC Berlin 2024.

Watch webinar

Must-know insights on CBD for pharma

What’s the difference between naturally sourced and synthetic cannabinoids? Or why is bioavailability a key consideration? Get the answers to common questions and bust misconceptions about CBD for pharma applications.

Explore FAQs

Ready to step confidently into cannabinoid research and development?

Let’s enter the pharma cannabinoids market with high-quality, science-backed products that meet patient needs and regulatory standards.

Partner with us

New CBD bioavailability study with CBtru®

New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.

Read more
Synthetic vs natural CBD ingredients: The differences and why they matter

Explore five differences between synthetic and natural CBD APIs to inform your next research and development project.

Read more
Ask the expert: how can ascorbic acid help mitigate nitrosamine risk in drug products?

Ascorbic acid, and other nitrite scavengers, have been shown to act as functional excipients in drug products that can reduce nitrosamine formation by blocking nitrosation reactions.

Read more

References

Ożarowski, M., Karpiński, T. M., Zielińska, A., Souto, E. B., & Wielgus, K. (2021). Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. International journal of molecular sciences, 22(9), 4294. https://doi.org/10.3390/ijms22094294
Argueta, D. A., Ventura, C. M., Kiven, S., Sagi, V., & Gupta, K. (2020). A Balanced Approach for Cannabidiol Use in Chronic Pain. Frontiers in pharmacology, 11, 561. https://doi.org/10.3389/fphar.2020.00561
O'Brien K. (2022). Cannabidiol (CBD) in Cancer Management. Cancers, 14(4), 885. https://doi.org/10.3390/cancers14040885